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Abstract. Event-based models (EBM) are a class of disease progression
models that can be used to estimate temporal ordering of neuropatholog-
ical changes from cross-sectional data. Current EBMs only handle scalar
biomarkers, such as regional volumes, as inputs. However, regional ag-
gregates are a crude summary of the underlying high-resolution images,
potentially limiting the accuracy of EBM. Therefore, we propose a novel
method that exploits high-dimensional voxel-wise imaging biomarkers:
n-dimensional discriminative EBM (nDEBM). nDEBM is based on an
insight that mixture modeling, which is a key element of conventional
EBMs, can be replaced by a more scalable semi-supervised support vec-
tor machine (SVM) approach. This SVM is used to estimate the degree of
abnormality of each region which is then used to obtain subject-specific
disease progression patterns. These patterns are in turn used for estimat-
ing the mean ordering by fitting a generalized Mallows model. In order to
validate the biomarker ordering obtained using nDEBM, we also present
a framework for Simulation of Imaging Biomarkers’ Temporal Evolu-
tion (SImBioTE) that mimics neurodegeneration in brain regions. SIm-
BioTE trains variational auto-encoders (VAE) in different brain regions
independently to simulate images at varying stages of disease progres-
sion. We also validate nDEBM clinically using data from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI). In both experiments, nDEBM
using high-dimensional features gave better performance than state-of-
the-art EBM methods using regional volume biomarkers. This suggests
that nDEBM is a promising approach for disease progression modeling.
1 Introduction
In 2015, approximately 46.8 million people were estimated to be living with
dementia, and by 2050 this number is expected to have increased to 131.5 mil-
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2lion [11]. Dementia is characterized by a cascade of neuropathological changes
which are quantified using several imaging and non-imaging biomarkers. Under-
standing how the different biomarkers progress from normal to abnormal state
after disease onset enables precise estimation of disease severity in an objective
and quantitative way. This can help in identifying individuals at risk of devel-
oping dementia as well as monitor the effectiveness of preventive and supportive
therapies.
Event-based models (EBM) are a class of disease progression models that esti-
mate the order in which biomarkers become abnormal during disease progression
using cross-sectional data [5,13,14,6]. It was reported in a recent paper on dis-
criminative EBM (DEBM) [13] that the EBMs are very sensitive to the quality
of biomarkers used for building the model. Hence, to infer the neuropathologi-
cal changes that occur during dementia accurately, good quality biomarkers are
important.
An essential step in an EBM involves mixture modeling to obtain biomarker
distributions in normal and abnormal classes [5,13]. This restricts the current
EBMs to only handle scalar biomarkers. In case of imaging biomarkers, regional
volumes from structural MRIs are often used [13,9,15,14,5]. However, regional
volumes are a crude summary of the high-dimensional information available from
structural MRI, resulting in suboptimal EBM performance, as shall be demon-
strated later in this paper. Therefore, we propose a novel method that exploits
voxel-wise imaging biomarkers: n-dimensional discriminative EBM (nDEBM).
Estimating the accuracy of ordering obtained by EBMs is not feasible as
ground-truth ordering is not known for a disease. In order to validate the pro-
posed method and compare its accuracy with that of existing state-of-the-art
EBM methods, we also present a framework for Simulation of Imaging Biomark-
ers’ Temporal Evolution (SImBioTE). SImBioTE uses variational auto-encoders
(VAE) to simulate neurodegeneration in brain regions. These regions are repre-
sented by a vector in the latent space of the VAE. Synthetic brain regions were
created by sampling latent representations corresponding to target degrees of
abnormality which were determined by a ground-truth ordering of disease pro-
gression. The generated synthetic brain regions were used as inputs for nDEBM,
and the regional aggregates were used as inputs for state-of-the-art EBMs to
evaluate the accuracies.
2 nDEBM
In Section 2.1, a brief introduction to the current DEBM [13] model is given. Sec-
tion 2.2, presents a novel framework to use semi-supervised SVMs in DEBM for
estimating posterior probabilities of abnormality for high-dimensional biomark-
ers. In Section 2.3, we use these posterior probabilities to estimate severity of
disease progression in an individual.
32.1 DEBM
In a cross-sectional dementia dataset (X) of M subjects (consisting of cognitively
normal (CN) and patients with dementia (DE)), let Xj denote a measurement of
biomarkers for subject j ∈ [1,M ], consisting of N scalar biomarker values xj,i.
As dementia is characterized by a cascade of neuropathological changes that
occurs over several years, even CN subjects can show some abnormal biomarker
values. On the other hand, in DE subjects, a proportion of biomarkers may still
have normal values, especialy in patients at an early disease stage. This leads to
label noise in the data and hence clinical labels cannot directly be propagated to
individual biomarkers. The DEBM model introduced in [13], similar to previously
proposed EBMs [5,6,14], fits a Gaussian mixture model (GMM) to construct the
normal and abnormal distributions. These are used to compute pre-event and
post-event likelihoods p(xj,i|¬Ei) and p(xj,i|Ei) respectively, where an event
Ei is defined as the corresponding biomarker becoming abnormal. The mixing
parameters are used as prior probabilities to convert these likelihoods to posterior
probabilities p(¬Ei|xj,i) and p(Ei|xj,i).
p(Ei|xj,i)∀i are used to estimate the subject-specific orderings sj . sj is es-
tablished such that:
sj 3 p(Esj(1)|xj,sj(1)) > p(Esj(2)|xj,sj(2)) > ... > p(Esj(N)|xj,sj(N)) (1)
Finally, DEBM computes the central event ordering S from the subject-
specific estimates sj . To describe the distribution of sj , a generalized Mallows
model is used. The central ordering is defined as the ordering that minimizes the
sum of distances to all subject-specific orderings sj , with probabilistic Kendall’s
Tau being the distance measure.
2.2 n-Dimensional Biomarker Progression
It was reported in [13] that the accuracy of EBMs depends on the quality of
biomarkers used to build the model. Greater separability of individual biomark-
ers results in estimation of more accurate event ordering. We hypothesize that
high-dimensional imaging biomarkers can increase the separability between the
normal and abnormal groups, thus improving the accuracy when used as inputs
to EBMs. The use of GMM in EBMs however restricts it to using only scalar
or low-dimensional biomarkers as GMMs do not scale well to high-dimensional
features. SVMs do scale well to high-dimensional features, but a supervised soft-
margin SVM cannot be used because of the large amounts of label noise (upto
one third of the elderly CN population could be in pre-symptomatic stages of
DE [12]). In this section, we present a way in which scalable semi-supervised
SVM classifiers can be used within the DEBM framework with high-dimensional
inputs.
Let Xj,i denote the high-dimensional imaging biomarker for brain region i.
Since the clinical diagnosis of the subject cannot be propagated to each region,
4the labels cannot be trusted while training a classifier. If we were to train a
classifier trusting these labels, independently on each biomarker (X∀j,i), we hy-
pothesize that labels of the data close to the decision boundary or on either side
of it cannot be completely trusted for that biomarker. For identifying the labels
that cannot be trusted for a biomarker, we propose to train a linear classifier
assuming equal class-priors. Fitting a non-linear classifier risks over-fitting to
the wrongly-labeled data whereas class-priors derived from labeled data could
be misleading as some of the labels might be wrong, for that biomarker.
For biomarker X∀j,i, subjects whose labels are preserved are considered as
labeled data (XL,i). Subjects whose labels have been rejected, along with any
prodromal subjects in the dataset are considered as unlabeled data (XU,i). Semi-
supervised classifiers can be used in this context for obtaining the decision bound-
ary for each biomarker.
To identify the subjects for whom labels can be trusted when considering
X∀j,i, we first train a linear SVM (f0;i) based on CN and DE subjects. After
rejecting labels that cannot be trusted (with distance d0;i < |dt| from the deci-
sion boundary), we use semi-supervised learning with EM [8] using linear SVM
with subject-specific costs [2] (f1;i, ..., fk+1;i) to iteratively refine the decision
boundary. The algorithm for this semi-supervised classification is given below:
Algorithm 1 Semi-Supervised SVM Learning with Subject-specific weights
1: for i ∈ {1...N} do
2: Train f0;i with X∀j∈{CN,DE},i as inputs
3: d0;∀j,i ← prediction of X∀j,i using f0;i
4: for j ∈ {1...M} do
5: if d0;j,i > |dt| then: XL,i ← Xj,i
6: else: XU,i ← Xj,i
7: Estimate pˆ0(Ei|XU,i) from d0;U,i (using Platt scaling [10]).
8: Train f1;i using X∀j,i using |pˆ0(Ei|XU,i) - pˆ0(¬Ei|XU,i)| as weights of XU,i.
9: Estimate pˆ1(Ei|XU,i) from d1;U,i
10: k ← 1
11: while ||pˆk(Ei|XU,i)− pˆk−1(Ei|XU,i)||2 <  do
12: Train fk+1;i using X∀j,i 3 |pˆk(Ei|XU,i) - pˆk(¬Ei|XU,i)| are weights of XU,i.
13: Estimate pˆk+1(Ei|XU,i) from dk+1;U,i.
14: k ← k + 1
15: Estimate pˆk+1(Ei|X∀j,i) from dk+1;∀j,i
16: p(Ei|Xj,i)← pˆk+1(Ei|Xj,i)
dt was chosen such that such that 5% of correctly classified data closest to
decision boundary are treated as unlabeled. The weights for XU,i in the above
algorithm is motivated based on [3]. It is done because unlabeled data close to
the decision boundary are not the ideal support vectors. The samples which are
farther away from the decision boundary of the previous iteration can be trusted
more as support vectors for the next iteration of training.
52.3 Patient Staging
Patient staging refers to the process of positioning individuals on a disease pro-
gression timeline characterized by the obtained event ordering. Patient stage (Υj)
is computed as an expectation of event-centers (λn) with respect to p(n, S,Xj),
where n denotes the possible discrete stages in the timeline characterized by N
biomarker events. Event-centers are the positions of the biomarker events on
a normalized disease progression timeline [0, 1], that capture relative distances
between events.
Υj =
∑N
n=1 λnp(n, S,Xj)∑N
n=1 p(n, S,Xj)
(2)
p(k, S,Xj) can be expressed in-terms of posterior probabilities of events obtained
from semi-supervised SVM as:
p (n, S,Xj) ∝
n∏
i=1
p
(
ES(i)|Xj,S(i)
)× N∏
i=n+1
p
(¬ES(i)|Xj,S(i)) (3)
3 SImBioTE: A Validation Framework
For validating classical EBMs and nDEBM in a unified framework, we extend
the framework developed in [16] for simulating datasets consisting of scalar
biomarkers, to be capable of generating datasets with realistic voxel-wise imag-
ing biomarkers. It was built on the assumption that the trajectory of biomarker
progression follows a sigmoid. Using a similar assumption, we consider the degree
of abnormality in different regions (aj,i) follows a sigmoidal trajectory.
aj,i(Ψ) =
1
1 + exp(−ρi(Ψ − ξj,i)) +  (4)
Ψ denotes disease stage of a subject which we take to be a random variable
distributed uniformly throughout the disease timeline.  is the equivalent of
measurement noise, which represents randomness in the measurement of abnor-
mality. ρi signifies the rate of progression of a biomarker, which we take to be
equal for all subjects for all biomarkers. It was shown in [13] that the perfor-
mance of EBMs is similar for equal ρi∀i and unequal ρi. ξj,i denotes the disease
stage at which the biomarker becomes abnormal.
After randomly choosing degrees of abnormalities for different regions, we
use a variational autoencoder (VAE) [7] for each region i, to generate 3D images
of these brain regions at a target degree of abnormality aj,i(Ψ). VAEs are neural
networks consisting of two main components: an encoder E which projects input
images into a lower dimensional space RK called the latent space, and a decoder
D which generates images from their hidden representation in the latent space
Z ∈ RK . Once the VAE has been trained using a large dementia dataset, a latent
representation Zj,i;t corresponding to the target degree of abnormality aj,i(Ψ)
6Fig. 1: Architecture of the Variational Autoencoder.
can be sampled in the latent space. The decoder D then generates a 3D image
D(Zj,i;t) corresponding to aj,i(Ψ). Below we describe the VAE used in this work,
and the sampling strategy in the latent space.
3.1 Implementation of the Convolutional Variational Autoencoder
Figure 1 summarizes the architecture of our VAE. We use a ReLU activation
after each convolutional layer, except after the last 1*1*1 convolutional layer.
We implemented the loss function as proposed by Kingma and Welling [7], with
mean-square-error (MSE) and Kullback-Leibler divergence. We optimized the
network with Adadelta [17].
3.2 Sampling Strategy in the Latent Space
To navigate in the latent space RKi of region i, we use Euclidean geometry. We
first build a scale vector Ui in the latent space to describe the range of the disease
from CN to DE. In order to generate a point Zj,i;t ∈ RKi at the target degree of
abnormality aj,i(Ψ), we first randomly sample a point Zj,i;s ∈ RKi , and translate
it along the direction of the scale vector Ui until we reach the target abnormality
aj,i(Ψ).
Scale Vector from Cognitively Normal to Dementia. To build the scale
vector Ui, we first compute the latent representations of all the images of region
i in the training dataset by projecting these images in the latent space RKi using
the encoder E. Then we use the binary labels – CN and DE – of each subject
7j to compute the means µi;CN ∈ RKi and µi;DE ∈ RKi , and standard deviations
σi;CN ∈ RKi and σi;DE ∈ RKi for each of the two categories respectively.
This is followed by computing the vector joining the two mean points as
ui = µi;DE − µi;CN . The idea is to create a vector Ui spanning the range of
the disease progression, from CN to DE. However, ui joins only the means, if
we want to capture the whole distribution, we need to lengthen this vector by
a multiple of the standard deviations, on both sides: for instance by 3σi;CN
in the CN side, and 3σi;DE on the DE side. To do so, we compute the scalar
projections of the standard deviations as σi;CNp = |σi;CN .ûi| and σi;DEp =
|σi;DE .ûi|, where ûi = ui/||ui||2. Now we can compute the new origin point (CN)
asO = µi;CN−3σi;CNpûi, and the new end point (DE) asM = µi;DE+3σi;DEpûi.
Finally, we can compute Ui = M −O. Note that Ûi = Ui/||Ui||2 = ûi.
Navigation for generation We first randomly sample a point Zj,i;s using the
mean and standard deviation of the latent representations of all subjects j for
region i. The degree of abnormality aj,i;s of this randomly sampled point Zj,i;s
can be computed as aj,i;s = OZj,i;s.Ûi/||Ui||2. To reach the target point Zj,i;t,
we need to translate the randomly sampled point Zj,i;s. This now can be done
by computing Zj,i;t = Zj,i;s + (aj,i;t − aj,i;s)Ui. To generate the corresponding
brain region we can now use the decoder and compute D(Zj,i;t).
4 Experiments and Results
This section describes the experiments performed to validate the proposed nDEBM
algorithm and also compare it with classical EBM [5] and DEBM [13] algorithms.
4.1 ADNI Data
We considered 1737 ADNI subjects (417 CN, 106 with significant memory con-
cern (SMC), 872 with mild cognitive impairment (MCI) and 342 AD subjects)
who had a 1.5T structural MRI (T1w) scan at baseline. This was followed by
multi-atlas brain extraction using the method described in [4]. Gray matter
(GM) volumes of segmented regions were regressed on age, sex and intra-cranial
volume (ICV) and the effects of these factors were subsequently corrected for.
Student’s t-test between CN and AD was performed on these confounding fac-
tor corrected GM volumes and 15 regions with smallest p-values were retained.
They were subsequently used as inputs for DEBM and EBM [5] models. The
optimization routine proposed in [13] was used to train the GMM in these two
models.
The T1w images were registered to a common template space based on the
method used in [4]. Probabilistic tissue segmentations were obtained for white
matter (WM), GM, and cerebrospinal fluid on the T1w image using the unified
tissue segmentation method [1]. The voxel-wise GM density maps were computed
based on the Jacobian of the local deformation map and the probabilistic GM
8volume. The GM density maps from the corresponding 15 regions were used as
inputs for nDEBM.
Model Validation Since the groundtruth ordering is not known in a clinical
setting, validation of these models was done based on the resulting patient stages
for classifying AD subjects from CN as well as for classifying MCI non-converters
(MCI-nc) from converters (MCI-c)?. We performed 10-fold cross-validation with
10 repetitions. The training set was used to train the three models. The disease
timeline created during training was used to stage the patients in the test-set.
Fig. 2: AUC measures when patient stages of nDEBM, DEBM and EBM were
used for classifying AD vs CN (left) and MCI-c vs MCI-nc (right). The error bar
represents the standard deviation in 10 random repetitions.
Figure 2 shows the results of 10 random repetitions of 10-fold cross-validation
on ADNI dataset. The error-bar shows the standard deviation of the AUCs when
the patient stages obtained from nDEBM, DEBM and EBM were used to classify
AD vs CN and MCI-c vs MCI-nc.
Uncertainty in Estimation Variation of the positions of the biomarker events
on a normalized disease progression timeline (event-centers) estimated by nDEBM
and DEBM was studied by creating 100 bootstrapped samples of the data and
applying nDEBM on those samples ??.
Figure 3 shows event-centers estimated by nDEBM and DEBM along with
the uncertainty in their estimations. The biomarkers are ordered along the y-axis
based on the event-ordering obtained by nDEBM.
? MCI converters are subjects who convert to AD within 3 years of baseline measure-
ment
?? EBM was left out of this experiment as the concept of event-centers was not intro-
duced for EBM.
9Fig. 3: Variation of event-centers estimated by nDEBM and DEBM in 100 boot-
strapped samples of the ADNI data. The error bar represents the standard de-
viation of the respective event-centers.
4.2 Simulation Data
In our experiments, ξj,i ∀j are random variables with N(µξi , Σξi). µξi were
equally spaced for different i. The value of Σξi was set to be ∆ξ where ∆ξ
is the difference in µξi of adjacent events. ρi was considered to be equal for all
biomarkers. Ψ of the simulated subjects were distributed uniformly throughout
the disease timeline.
We first trained 15 VAEs (one per selected region) on the GM density maps
of the ADNI dataset. Then we generated - as detailed in Section 3 - images
for these 15 regions and for 1737 artificial subjects according to pre-computed
degrees of abnormality as defined in Equation 4. These degrees of abnormality
are different for each region and each subject. We repeated this process 10 times,
with different random simulations. The voxel-wise GM density maps of regions
were used for obtaining the ordering using nDEBM. The GM volume of the
simulated regions (computed by integrating the GM density map over the region
of interest) were used as biomarkers for DEBM and EBM.
SimBioTE results depicting Lateral occipitotemporal gyrus atrophy in sim-
ulated images is shown in Figure 4. The images thus generated were used for
validating different EBM methods.
The errors made by different EBM methods on SImBioTE data are shown in
Figure 5. The estimated ordering and the ground-truth orderings were compared
using Kendall’s Tau distance.
5 Discussions
We proposed a novel method (nDEBM) that exploits high-dimensional voxel-
wise imaging biomarkers for event-based modeling using semi-supervised SVM.
This was validated based on ADNI dataset, where the spatial spread of structural
10
Fig. 4: An example of Lateral occipitotemporal gyrus (right) atrophy as simu-
lated by SImBioTE. The interpolation spans the full range Ui, as described in
section 3. Left is normal (CN) and right is abnormal (DE). The two rows shows
disease progression in two different simulated subjects.
Fig. 5: Inaccuracies, as measured by Kendall’s Tau distance from groundtruth,
of nDEBM, DEBM and EBM. The error bar represents the standard deviation
of the errors made in 10 repetitions of simulations.
abnormality was estimated based on a cross-sectional dataset. However this is an
indirect validation of the orderings based on accuracy of the estimated patient
stages, since the ground-truth ordering for clinical data is unknown.
To unambiguously validate the orderings obtained, we also proposed a new
simulation framework (SImBioTE) to simulate voxel-wise imaging biomarkers
based on training VAEs on different regions. It is known that GM tissue is lost
in AD progression. Therefore the voxel-wise GM density maps will become darker
as the disease progresses, as can be observed in Figure 4. It was also observed in
Figure 4 that simulated regions for different subjects shows considerable varia-
tions. This shows that the simulation framework is capable of generating datasets
with realistic atrophy and with good inter-subject variability. This, in combina-
tion with the scalar biomarkers’ simulation framework, results in images where
the disease progression in different regions can be controlled. However, a more
thorough validation of the simulation framework by comparing the atrophy pat-
terns of the simulated data with that of real-life longitudinal data is needed to
understand the effect of different model parameters. Possible extensions of SIm-
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BioTE includes simulating whole brain images from these independent regions,
which can be used to validate wider range of disease progression models.
The datasets simulated by SImBioTE were used for inputs for different
EBMs. It was observed in Figure 5 that the orderings obtained by nDEBM are
much closer to the ground-truth as compared to DEBM and EBM. It was also
observed in Figure 2 that the patient stages obtained by nDEBM delineates AD
and CN subjects much better than the ones obtained by DEBM and EBM. The
AUCs of classifying MCI-c vs MCI-nc are also marginally better for nDEBM as
compared to the other two methods. These experiments serve as a validation for
our initial hypothesis that increasing the dimensionality of the inputs helps in
better delineation of normal and abnormal regions, which increases the accuracy
of the resulting ordering. It can hence be concluded that the voxel-wise data
helps nDEBM in estimating the disease progression more accurately than re-
gional volumes. However, the choice of hyper-parameters in nDEBM (for e.g. dt,
SVM slack parameters) was done ad-hoc. The effect they have on the accuracy
of the resulting ordering needs to be studied through more rigorous validation
experiments.
The difference in event orderings obtained by nDEBM and DEBM as ob-
served in Figure 3 suggests that the two types of inputs can lead to very differ-
ent results. Hence, computing regional aggregates, such as volumes, and using
that as inputs for EBMs as done in [13,9,15,14,5] is not an optimal choice for
estimating the spatial progression of disease.
6 Conclusion
We hypothesized that high-dimensional imaging biomarkers would result in bet-
ter delineation of normal and abnormal regions thus leading to more accurate
event-based models. We hence proposed a novel method (nDEBM) that exploits
high-dimensional voxel-wise imaging biomarkers based on semi-supervised SVM
to estimate temporal ordering of neuropathological changes in the brain struc-
ture using cross-sectional data. We also proposed a simulation framework (SIm-
BioTE) using variational auto-encoders that mimics neurodegeneration in brain
regions to validate nDEBM. Furthermore, we applied nDEBM framework to a
set of 1737 subjects from ADNI dataset for clinically validating the method. In
both experiments, nDEBM using high-dimensional features gave better perfor-
mance than state-of-the-art EBM methods using regional volume biomarkers.
This served as a validation for our initial hypothesis. nDEBM thus presents a
new paradigm for estimating spatial progression of dementia.
Acknowledgement
This project has received funding from the European Unions Horizon 2020 re-
search and innovation programme under grant agreement No. 666992. E.E. Bron
12
is supported by the Hartstichting (PPP Allowance, 2018B011). F. Dubost is sup-
ported by The Netherlands Organisation for Health Research and Development
(ZonMw) Project 104003005.
References
1. Ashburner, J., Friston, K.J.: Unified segmentation. NeuroImage 26(3), 839 – 851
(2005)
2. Brefeld, U., Geibel, P., Wysotzki, F.: Support vector machines with example de-
pendent costs. In: Machine Learning: ECML 2003. pp. 23–34. Springer Berlin Hei-
delberg, Berlin, Heidelberg (2003)
3. Brefeld, U., Scheffer, T.: Co-em support vector learning. In: Proceedings of the
Twenty-first International Conference on Machine Learning. pp. 16–. ICML ’04,
ACM, New York, NY, USA (2004)
4. Bron, E.E., et al.: Diagnostic classification of arterial spin labeling and structural
MRI in presenile early stage dementia. Human Brain Mapping 35(9), 4916–4931
(2014)
5. Fonteijn, H.M., et al.: An event-based model for disease progression and its appli-
cation in familial Alzheimer’s disease and Huntington’s disease. NeuroImage 60(3),
1880 – 1889 (2012)
6. Huang, J., Alexander, D.: Probabilistic event cascades for Alzheimer’s disease. In:
Advances in Neural Information Processing Systems 25, pp. 3095–3103. Curran
Associates, Inc. (2012)
7. Kingma, D.P., Welling, M.: Auto-encoding variational bayes. stat 1050, 1 (2014)
8. Nigam, K., Mccallum, A.K., Thrun, S., Mitchell, T.: Text classification from la-
beled and unlabeled documents using em. Machine Learning 39(2), 103–134 (May
2000)
9. Oxtoby, N.P., Alexander, D.C.: Imaging plus X: multimodal models of neurode-
generative disease. Current Opinion in Neurology 30(4), 371–379 (2017)
10. Platt, J.: Probabilistic outputs for support vector machines and comparisons to
regularized likelihood methods. Advances in Large Margin Classifiers 10(3) (1999)
11. Prince, M., Wimo, A., Guerchet, M., Ali, G.C., Wu, Y.T., Prina, M.: World
Alzheimer’s report 2015, the global impact of dementia: An analysis of prevalence,
incidence, cost and trends. Alzheimer’s Disease Int’l (2015)
12. Schott, J.M., Bartlett, J.W., Fox, N.C., Barnes, J., for ADNI: Increased brain
atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1−
42. Annals of Neurology 68(6), 825–834 (2010)
13. Venkatraghavan, V., Bron, E.E., Niessen, W.J., Klein, S.: Disease progression time-
line estimation for Alzheimer’s disease using discriminative event based modeling.
NeuroImage 186, 518 – 532 (2019)
14. Young, A.L., et al.: A data-driven model of biomarker changes in sporadic
Alzheimer’s disease. Brain 137(9), 2564–2577 (2014)
15. Young, A.L., et al.: Uncovering the heterogeneity and temporal complexity of neu-
rodegenerative diseases with subtype and stage inference. Nature Communications
9, 4273 (2018)
16. Young, A.L., Oxtoby, N.P., Ourselin, S., Schott, J.M., Alexander, D.C.: A simula-
tion system for biomarker evolution in neurodegenerative disease. Medical Image
Analysis 26(1), 47 – 56 (2015)
17. Zeiler, M.D.A.: An adaptive learning rate method. arxiv preprint. arXiv preprint
arXiv:1212.5701 (2012)
